


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

BOTTAZZI et al.

Atty. Ref.: 2801-18

Serial No. 09/555,473

Group: 1644

Filed: February 26, 2002

Examiner: NOLAN

For: PHARMACEUTICAL COMPOSITIONS CONTAINING THE
LONG PENTRAXIN PTX3

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 16, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449. Copies of the listed documents have been previously supplied and return of an initialized copy of the attached PTO-1449 Form is requested to confirm the documents have been considered. Further copies of the cited documents are not believed to be required however the Examiner is requested to advise the undersigned if otherwise.

This paper is submitted in accordance with:


- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37

CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

2801-18

09/555,473

APPLICANT

BOTTAZZI et al.

FILING DATE

GROUP

February 26, 2002

1644

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Dictionary Definition: excipient, internet web site dict.die.net , July 30, 2003
	The Merck Index, Eleventh Edition, Carboxymethylcellulose Sodium, page 278
	Inositol (Vitamin B8), BluePrint for Health, internet web site blueprint.bluecrossmn.com , July 31, 2003, pp 1-5
	Moore et al, Myo-inositol in psychiatry, Temporal Dissociation between lithium-induced changes in frontal lobe...illness, Abstract, pp 1-2
	Folic Acid, internet web site suprahealth.com , July 31, 2003, pp 1-3
	Choline Chloride, October 1995, 0853
	Therapeutic Category and Biological Activity Index, Merck & Co., Inc. 2002
	The Merck Manual, Section 1 (48), Chapter 3(49), Section 16 (1660), Chapter 202 (1661)
	ICH Harmonised Tripartite Guideline, Stability Testing of New Drug Substances and Products Q1A (R2), February 6, 2003
	Butterworths Medical Dictionary, Second Edition, p 628
	Fordham et al, Technical Reports Vol. 3, No. 3, Albany Molecular Research, Inc., Definition of Frequently Used Terms in Regulatory Affairs and Quality Assurance, pp 7-11

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)